CClinicalTrials.gg
Sign In
Status unknownNCT03580850Updated Jul 13, 2018

MRI Scan and Intra-labyrinthine Schwannoma

An observational study in Schwannoma, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-07-13.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)

02

Conditions studied

  • Schwannoma

Browse trials for

Keywords

  • intra labyrinthine schwannoma
  • schwannoma
  • magnetic resonance imaging (MRI)
  • gadolinium
  • T2 weighted gradient echo
03

In context

Neurilemmoma

82 studies on the registry are indexed under Neurilemmoma; 21 are open to participants now.

This study's planned enrollment of 30 is below the median of 63 across 30 observational studies indexed under Neurilemmoma.

Browse Neurilemmoma studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient having intra-labyrinthine schwannoma

Inclusion criteria

  • Age 18-80 years
  • Have intra-labyrinthine schwannoma
  • Have benefited from an MRI with gadolinium injection on the MRI 3T with interpretable sequences of good quality
  • Subject giving their consent for their participation
  • Subjects who benefited, between 2009 and 2016, from an MRI of the external auditory canals, with gadolinous product injection and on the 3 Tesla MRI, in which a diagnosis of intra labyrinthine schwannoma was made

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • OtherNo intervention in this restrospective study

    This study is an obervational study

06

What researchers measure

Primary outcomes

  1. Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA alone

    Time frame: 1 hour after the realization of the MRI

07

Study locations

1 of 1 sites recruiting
  • Service Imagerie 1
    Strasbourg, 67098, France
    • Francis VEILLON, MD, PhD · Contact · 33 3 88 12 78 65
    • Aïna VENKATASAMY, MD · Contact · aina.venkatasamy@chru-strasbourg.fr · 33 3 88 12 78 65
    • Francis VEILLON, MD, PhD · Principal investigator
    • Aïna VENKATASAMY, MD · Sub investigator
    • Anne KAROL, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03580850
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Feb 2, 2018
Primary completion
Feb 2019 (estimated)
Completion
Feb 2019 (estimated)
Last update
Jul 13, 2018

Study contacts

Francis VEILLON, MD, PhD
Contact
Francis.veillon@chru-strasbourg.fr
33 3 88 12 78 65
Aïna VENKATASAMY, MD
Contact
aina.venkatasamy@chru-strasbourg.fr
33 3 88 12 78 65
Francis VEILLON, MD, PhD
study director · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neurilemmoma→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion